help button home button Am J Pathol R & D Systems
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Order Full text via Infotrieve
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Charpin, C.
Right arrow Articles by Toga, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Charpin, C.
Right arrow Articles by Toga, M.

American Journal of Pathology, Vol 132, 199-211, Copyright © 1988 by American Society for Investigative Pathology

REGULAR ARTICLES

Multiparametric analysis (SAMBA 200) of the progesterone receptor immunocytochemical assay in nonmalignant and malignant breast disorders

C Charpin, J Jacquemier, L Andrac, H Vacheret, MC Habib, B Devictor, MN Lavaut and M Toga
Pathology Department, Centre Hospitalo-Universitaire Timone, Marseille, France.

An immunocytochemical assay using monoclonal anti-progesterone receptor (PR-ICA) was performed in nonmalignant (N = 57) and malignant (N = 200) breast disorders. The results were analyzed with a computerized system of image analysis referred to as SAMBA and correlated with binding assays (DCC), and with standard histopathologic findings. It was shown that there was a correlation between 1) the PR-ICA and the binding assays (91.5%), and 2) between the binding assays and the multiparametric computerized (SAMBA) analysis of the PR-ICA. It was also shown that SAMBA provides an accurate, reliable, and reproducible evaluation of PR-ICA that is complementary to binding assays and constitutes a standardized method of evaluating the heterogeneity of the progesterone receptor (PR) distribution in tumors. It is concluded that SAMBA analysis of both the PR-ICA and estrogen receptor (ER-ICA) should improve the prognostic evaluation and the prediction of responsiveness to endocrine therapy in breast carcinomas.


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
C. Charpin, J.-P. Dales, S. Garcia, S. Carpentier, A. Djemli, L. Andrac, M.-N. Lavaut, C. Allasia, and P. Bonnier
Tumor Neoangiogenesis by CD31 and CD105 Expression Evaluation in Breast Carcinoma Tissue Microarrays
Clin. Cancer Res., September 1, 2004; 10(17): 5815 - 5819.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1988 by the American Society for Investigative Pathology.